This is real vindication of our long-ago (Fall 2024) rather bold predictions. [I actually think it was around $29, when we first said $85 would be fairer.]

Moderna is a great company, well run and very careful in its research spending. Focuses on things that it believes it truly can tackle. And then it tackles them with gusto.

Here’s the latest from just one of many similar Wall Street “rag” stories over the past three days, so I won’t link it, but this is how they view it — and with that I will be off — gallivanting across the lush green countryside.

…Wolfe Research upgrades Moderna to Peer Perform and describes the melanoma trial as de risking the intismeran platform, with a clearer regulatory path in adjuvant melanoma and estimated unadjusted peak sales across four indications of $9.2 billion….

Barclays, UBS, Goldman Sachs, Morgan Stanley and RBC Capital all move price targets materially higher, linking their revisions to the Phase 3 melanoma success and to higher modeled contribution from intismeran….

Here, now, in the land of my ancestors… these extended trips completely renew my soul!

नमस्ते